Literature DB >> 23455501

Reversion of somatic mutations of the respiratory syncytial virus-specific human monoclonal antibody Fab19 reveal a direct relationship between association rate and neutralizing potency.

John T Bates1, Christopher J Keefer, Thomas J Utley, Bruno E Correia, William R Schief, James E Crowe.   

Abstract

The role of affinity in determining neutralizing potency of mAbs directed against viruses is not well understood. We investigated the kinetic, structural, and functional advantage conferred by individual naturally occurring somatic mutations in the Ab H chain V region of Fab19, a well-described neutralizing human mAb directed to respiratory syncytial virus. Comparison of the affinity-matured Ab Fab19 with recombinant Fab19 Abs that were variants containing reverted amino acids from the inferred unmutated ancestor sequence revealed the molecular basis for affinity maturation of this Ab. Enhanced binding was achieved through mutations in the third H chain CDR (HCDR3) that conferred a markedly faster on-rate and a desirable increase in antiviral neutralizing activity. In contrast, most somatic mutations in the HCDR1 and HCDR2 regions did not significantly enhance Ag binding or antiviral activity. We observed a direct relationship between the measured association rate (Kon) for F protein and antiviral activity. Modeling studies of the structure of the Ag-Ab complex suggested the HCDR3 loop interacts with the antigenic site A surface loop of the respiratory syncytial virus F protein, previously shown to contain the epitope for this Ab by experimentation. These studies define a direct relationship of affinity and neutralizing activity for a viral glycoprotein-specific human mAb.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23455501      PMCID: PMC3608519          DOI: 10.4049/jimmunol.1202964

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody.

Authors:  A Desmyter; K Decanniere; S Muyldermans; L Wyns
Journal:  J Biol Chem       Date:  2001-05-07       Impact factor: 5.157

2.  Thermodynamic and kinetic aspects of antibody evolution during the immune response to hapten.

Authors:  Takuma Sagawa; Masayuki Oda; Miyuki Ishimura; Koji Furukawa; Takachika Azuma
Journal:  Mol Immunol       Date:  2003-03       Impact factor: 4.407

3.  Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations.

Authors:  Jeffrey J Gray; Stewart Moughon; Chu Wang; Ora Schueler-Furman; Brian Kuhlman; Carol A Rohl; David Baker
Journal:  J Mol Biol       Date:  2003-08-01       Impact factor: 5.469

4.  HIV vaccine design and the neutralizing antibody problem.

Authors:  Dennis R Burton; Ronald C Desrosiers; Robert W Doms; Wayne C Koff; Peter D Kwong; John P Moore; Gary J Nabel; Joseph Sodroski; Ian A Wilson; Richard T Wyatt
Journal:  Nat Immunol       Date:  2004-03       Impact factor: 25.606

Review 5.  Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).

Authors:  Jessie R Groothuis; Hiroshi Nishida
Journal:  Pediatr Int       Date:  2002-06       Impact factor: 1.524

6.  Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization.

Authors:  B R Murphy; A V Sotnikov; L A Lawrence; S M Banks; G A Prince
Journal:  Vaccine       Date:  1990-10       Impact factor: 3.641

7.  Generation of recombinant human monoclonal antibodies to rotavirus from single antigen-specific B cells selected with fluorescent virus-like particles.

Authors:  Jörn Hendrik Weitkamp; Nicole Kallewaard; Koichi Kusuhara; Dino Feigelstock; Ninguo Feng; Harry B Greenberg; James E Crowe
Journal:  J Immunol Methods       Date:  2003-04-01       Impact factor: 2.303

Review 8.  Basic epidemiology and immunopathology of RSV in children.

Authors:  J Handforth; J S Friedland; M Sharland
Journal:  Paediatr Respir Rev       Date:  2000-09       Impact factor: 2.726

9.  Infant and adult human B cell responses to rotavirus share common immunodominant variable gene repertoires.

Authors:  Jörn-Hendrik Weitkamp; Nicole Kallewaard; Koichi Kusuhara; Elizabeth Bures; John V Williams; Bonnie LaFleur; Harry B Greenberg; James E Crowe
Journal:  J Immunol       Date:  2003-11-01       Impact factor: 5.422

Review 10.  Respiratory syncytial virus--viral biology and the host response.

Authors:  D Hacking; J Hull
Journal:  J Infect       Date:  2002-07       Impact factor: 6.072

View more
  11 in total

1.  STAT4 deficiency fails to induce lung Th2 or Th17 immunity following primary or secondary respiratory syncytial virus (RSV) challenge but enhances the lung RSV-specific CD8+ T cell immune response to secondary challenge.

Authors:  Daniel E Dulek; Dawn C Newcomb; Shinji Toki; Kasia Goliniewska; Jacqueline Cephus; Sara Reiss; John T Bates; James E Crowe; Kelli L Boyd; Martin L Moore; Weisong Zhou; R Stokes Peebles
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

2.  Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline.

Authors:  Ivelin S Georgiev; Rebecca S Rudicell; Kevin O Saunders; Wei Shi; Tatsiana Kirys; Krisha McKee; Sijy O'Dell; Gwo-Yu Chuang; Zhi-Yong Yang; Gilad Ofek; Mark Connors; John R Mascola; Gary J Nabel; Peter D Kwong
Journal:  J Immunol       Date:  2014-01-03       Impact factor: 5.422

3.  Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates.

Authors:  John T Bates; Jennifer A Pickens; Jennifer E Schuster; Monika Johnson; Sharon J Tollefson; John V Williams; Nancy L Davis; Robert E Johnston; Nancy Schultz-Darken; James C Slaughter; Frances Smith-House; James E Crowe
Journal:  Vaccine       Date:  2016-01-07       Impact factor: 3.641

4.  Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein.

Authors:  John T Bates; Christopher J Keefer; James C Slaughter; Daniel W Kulp; William R Schief; James E Crowe
Journal:  Virology       Date:  2014-03-03       Impact factor: 3.616

5.  Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.

Authors:  Annalisa Meola; Alexander W Tarr; Patrick England; Luke W Meredith; C Patrick McClure; Steven K H Foung; Jane A McKeating; Jonathan K Ball; Felix A Rey; Thomas Krey
Journal:  J Virol       Date:  2014-12-03       Impact factor: 5.103

6.  Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10.

Authors:  Kathryn A K Finton; Della Friend; James Jaffe; Mesfin Gewe; Margaret A Holmes; H Benjamin Larman; Andrew Stuart; Kevin Larimore; Philip D Greenberg; Stephen J Elledge; Leonidas Stamatatos; Roland K Strong
Journal:  PLoS Pathog       Date:  2014-09-25       Impact factor: 6.823

7.  HIV-1 Vaccine-elicited Antibodies Reverted to Their Inferred Naive Germline Reveal Associations between Binding Affinity and in vivo Activation.

Authors:  Kaifan Dai; Salar N Khan; Yimeng Wang; Linling He; Javier Guenaga; Jidnyasa Ingale; Christopher Sundling; Sijy O'Dell; Krisha McKee; Ganesh Phad; Martin Corcoran; Richard Wilson; John R Mascola; Jiang Zhu; Yuxing Li; Gunilla B Karlsson Hedestam; Richard T Wyatt
Journal:  Sci Rep       Date:  2016-02-16       Impact factor: 4.379

8.  A Rough Energy Landscape to Describe Surface-Linked Antibody and Antigen Bond Formation.

Authors:  Laurent Limozin; Pierre Bongrand; Philippe Robert
Journal:  Sci Rep       Date:  2016-10-12       Impact factor: 4.379

9.  Affinity maturation is required for pathogenic monovalent IgG4 autoantibody development in myasthenia gravis.

Authors:  Miriam L Fichtner; Casey Vieni; Rachel L Redler; Ljuvica Kolich; Ruoyi Jiang; Kazushiro Takata; Panos Stathopoulos; Pablo A Suarez; Richard J Nowak; Steven J Burden; Damian C Ekiert; Kevin C O'Connor
Journal:  J Exp Med       Date:  2020-12-07       Impact factor: 14.307

10.  The influence of proline isomerization on potency and stability of anti-HIV antibody 10E8.

Authors:  Miklos Guttman; Neal N Padte; Yaoxing Huang; Jian Yu; Gabriel J Rocklin; Brian D Weitzner; Michele Scian; David D Ho; Kelly K Lee
Journal:  Sci Rep       Date:  2020-08-31       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.